Carcinoma, Basal Cell
42
2
3
26
Key Insights
Highlights
Success Rate
87% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
9.5%
4 terminated out of 42 trials
86.7%
+0.2% vs benchmark
17%
7 trials in Phase 3/4
23%
6 of 26 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 26 completed trials
Clinical Trials (42)
Post-occlusive Reactive Hyperemia and Basal-cell Carcinoma
HIFU for Treatment of Non-nodular and Recurrent BCC
Laser Treatment of Basal Cell Carcinoma Under Imaging Guidance
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
PD-1 in Patients With Advanced Basal Cell Carcinoma Who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy, or Were Intolerant of Prior Hedgehog Pathway Inhibitor Therapy
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Nicotinamide Chemoprevention for Keratinocyte Carcinoma in Solid Organ Transplant Recipients - Pivotal Trial
Cytodiagnosis of Basal Cell Carcinoma and Actinic Keratosis Using Papanicolaou and May-grunwald-giemsa Stained Tissue Smear
Intratumoral Administration of Daromun in Non-melanoma Skin Cancer Patients
Skin Cancer Prevention With Nicotinamide in Transplant Recipients - Pilot Trial
Topical Laser-assisted Combination Chemotherapy for Basal Cell Carcinoma- a Clinical Study
Aldara for the Treatment of Large and/or Multiple sBCC
VISmodegib for ORbital and Periocular Basal Cell Carcinoma
CSP #562 - The VA Keratinocyte Carcinoma Chemoprevention Trial
Spanish Registry of Mohs Surgery
To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma
Efficiency of Presurgical Basal Cell Carcinoma Margin Mapping
EPR Tumor Oximetry With CE India Ink
Reflectance Confocal Microscopy in Basal Cell Carcinoma
Observational Study to Determine the Effectiveness and Safety of Vismodegib (Erivedge®) in Participants With Locally Advanced Basal Cell Carcinoma (laBCC)